{"doi":"10.1371/journal.ppat.1012817","title":"Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection","abstract":"The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP). Cryo-EM and biochemical data revealed that Nanosota-EB1 binds to the glycan cap of GP1, preventing its protease cleavage, while Nanosota-EB2 binds to critical membrane-fusion elements in GP2, stabilizing it in the pre-fusion state. Nanosota-EB2 is a potent neutralizer of EBOV infection in vitro and offers excellent protection in a mouse model of EBOV challenge, while Nanosota-EB1 provides moderate neutralization and protection. Nanosota-EB1 and Nanosota-EB2 are the first nanobodies shown to inhibit authentic EBOV. Combined with our newly developed structure-guided in vitro evolution approach, they lay the foundation for nanobody-based therapies against EBOV and other viruses within the ebolavirus genus.","journal":"PLoS Pathogens","year":2024,"id":452094,"datarank":0.24184151458279463,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.03389736041481101,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.03389736041481101,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":2,"citers_with_citation_signal":2,"citers_with_endowment":2,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9506,"is_data_producer":true,"deposit_databanks":{"PDB":["9BSU","EMD-44872"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":103756,"name":"Gang Ye","orcid":"0000-0001-6034-2174","position":1,"is_corresponding":false},{"id":1270028,"name":"Kimberly M. Morsheimer","orcid":null,"position":2,"is_corresponding":false},{"id":1060861,"name":"Alise Mendoza","orcid":"0000-0003-2966-8031","position":3,"is_corresponding":false},{"id":1258942,"name":"Hailey Turner‐Hubbard","orcid":null,"position":4,"is_corresponding":false},{"id":1061200,"name":"Morgan Herbst","orcid":null,"position":5,"is_corresponding":false},{"id":484525,"name":"Benjamin W. Spiller","orcid":"0000-0001-5397-1028","position":6,"is_corresponding":false},{"id":866117,"name":"Brian E. Wadzinski","orcid":"0000-0002-2980-3697","position":7,"is_corresponding":false},{"id":325401,"name":"Brett Eaton","orcid":"0000-0002-3060-2913","position":8,"is_corresponding":false},{"id":562818,"name":"Manu Anantpadma","orcid":"0000-0001-5796-532X","position":9,"is_corresponding":false},{"id":355637,"name":"Ge Yang","orcid":"0000-0002-0415-0933","position":10,"is_corresponding":false},{"id":631794,"name":"Bin Liu","orcid":"0000-0001-6485-7669","position":11,"is_corresponding":false},{"id":266495,"name":"Robert A. Davey","orcid":"0000-0001-9168-2892","position":12,"is_corresponding":false},{"id":103706,"name":"Fang Li","orcid":"0000-0002-1958-366X","position":13,"is_corresponding":false},{"id":1060860,"name":"Fan Bu","orcid":"0000-0002-6965-3072","position":0,"is_corresponding":true}],"reference_count":66,"raw_metadata":null,"created_at":"2026-07-19T02:02:50.407779Z","pmid":"39715280","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}